ArticleBMC urology2026
Outcomes of Retzius-sparing robot-assisted radical prostatectomy in men aged ≥ 75 years.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Disproportionate expansion of radical prostatectomy among older men in Japan in the robotic surgery era: a nationwide descriptive time series analysis.Journal of robotic surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRobot-assisted radical prostatectomy using the Retzius-sparing approach (RS-RARP) is increasingly adopted, yet evidence regarding outcomes in men aged ≥ 75 years remains extremely limited.
objectiveThis study evaluated perioperative, oncological, and functional outcomes of RS-RARP in elderly patients.
methodsA total of 608 men who underwent RS-RARP between 2016 and 2023 were included. Patients were divided into two groups: <75 years (n = 548) and ≥ 75 years (n = 60). Preoperative characteristics, surgical parameters, complications, pathological findings, and continence status up to 12 months were compared.
resultsMen aged ≥ 75 years presented more often with larger prostates, higher biopsy ISUP grades, and more intermediate/high-risk disease. Non–nerve-sparing procedures were more frequently performed in the elderly group and operative time, blood loss, hospital stay and complication rates were similar between the two groups. The rate of early urinary continence recovery was lower among older patients, but by 12 months continence rates were nearly identical. Elderly patients showed more advanced pathological tumor stages, more PSA persistence and a higher need for adjuvant hormonal therapy, while rates of positive surgical margins and biochemical recurrence were comparable.
conclusionsRS-RARP can be safely offered to selected patients aged ≥ 75 years without compromising perioperative safety or oncological control. Despite delayed continence recovery, one-year functional outcomes are equivalent, supporting RS-RARP as a viable treatment option for appropriately chosen elderly men with localized prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.